Yuan Yuan

8PUBLICATIONS
9CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsMedical devices
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|May 04, 2026
A real-world study on treatment after TKI progression in HER2-positive MBC.

|Feb 17, 2026
Phase II trial of anlotinib-chemotherapy combination in pretreated HER2-negative metastatic breast cancer: therapeutic efficacy and proteomic biomarker profiling.

Ting Xu, Quan Gu, Shiyi Li

|Jan 01, 2025
The Effects of Anlotinib Combined with Chemotherapy following Progression on Cyclin-Dependent Kinase 4/6 Inhibitor in Hormone Receptor-Positive Metastatic Breast Cancer.

Ting Xu, Weili Xiong, Lili Zhang

|Nov 16, 2024
Real-world application of disitamab vedotin (RC48-ADC) in patients with breast cancer with different HER2 expression levels: efficacy and safety analysis.

Ke Wang, Ting Xu, Jing Wu

|Aug 09, 2024
UGT1A7 altered HER2-positive breast cancer response to trastuzumab by affecting epithelial-to-mesenchymal transition: A potential biomarker to identify patients resistant to trastuzumab treatment.

Cong Wang, Chenguang Bai, Zhe Zhang

|Jan 25, 2024
Efficacy and safety of nanoparticle albumin-bound paclitaxel in taxane-pretreated metastatic breast cancer patients.

Weili Xiong, Ting Xu, Xiao Liu

Pageof 2

Frequent Collaborators

5 joint publications

Ting Xu

2 joint publications

Lili Zhang

2 joint publications

Shiyi Li

1 joint publications

Huanyao Gao